Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05127421 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 77
- Enrollment target
NCT05127421 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 77 participants.
The verdict
NCT05127421, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 77 participants
- Enrollment target
Study Summary
This is a randomized, double blind, vehicle controlled Phase 2 study with a 4-week open label extension in adolescent and adult participants with atopic dermatitis and head and/or neck involvement. It is intended to compare the efficacy and safety of ruxolitinib cream 1.5% BID versus vehicle cream, then further evaluate ruxolitinib cream as maintenance during the open label extension period.
Interventions
- DRUG Vehicle
- DRUG Ruxolitinib cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2021-11-10 |
| Est. Completion | 2023-09-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05127421
The ClinicalTrials.gov registry entry for NCT05127421 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT05127421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05127421 about?
NCT05127421 is a clinical study titled "Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement". This is a randomized, double blind, vehicle controlled Phase 2 study with a 4-week open label extension in adolescent and adult participants with atopic dermatitis and head and/or neck involvement. It is intended to compare the efficacy and safety of ruxolitinib cream 1.5% BID versus vehicle cream, ...
What is the current status of trial NCT05127421?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 77 participants. The study started on 2021-11-10. Estimated completion is 2023-09-29.
What interventions are being tested in trial NCT05127421?
The interventions under investigation include: Vehicle (DRUG), Ruxolitinib cream (DRUG).
Who is sponsoring clinical trial NCT05127421?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.